IL1B and arthritic joint disease: It was observed that even the lowest dosage of 0.125% CLA was sufficient to decrease plasma cytokines (IL-1β, TNF-α, IL-6) and reduce arthritis symptoms (paw swelling and clinical scores) by the end of the 84-day trial [188].